Novo Nordisk
Search results
During the first six months of 2024, LEO Pharma continued to execute on its strategy with the dermatology portfolio as the primary growth driver. With revenue growth of 11% in constant exchange rates (CER) and EBITDA margin of 9% in the first half of the year, LEO Pharma remains on course to deliver solid financial performance for the full year ...
The LEO Foundation is one of Denmark’s largest commercial foundations and an engaged owner of the pharmaceutical company LEO Pharma.
From our earliest history, LEO Pharma has gone beyond conventional approaches to serve patients and meet their needs. Today we remain committed to making a fundamental difference for those who need us most in medical dermatology.
LEO Pharma is developing an even deeper understanding of hard-to-treat skin diseases by forging external partnerships with innovators while we evolve our current offerings
We are constantly searching for new colleagues who share our passion and ambition. With the right people on board, LEO Pharma can continue to make a fundamental difference for those who need us most in medical dermatology.
Historically, LEO Pharma owes its success over the last 100 years to LEO People with a strong passion for innovation, customer focus, integrity and adaptability. LEO People with the will to expand and the capability to consolidate.
Sep 27, 2024 · “The positive outcomes observed in the TRACE study not only highlight the real-world results of Adtralza/Adbry but also reinforce LEO Pharma's dedication to addressing the diverse needs of patients. With five late-breakers at this conference, we are proud to showcase our extensive scientific program and the significant strides we are making ...
You can contact LEO Pharma A/S by filling in the following form. All fields marked with * must be filled in. You will receive a copy of the form by e-mail once you have pressed "Submit".
At LEO Pharma, we help people with skin diseases live fulfilling lives by advancing dermatology beyond the skin. Learn more about our available job opportunities and life at LEO Pharma here.
Sep 26, 2024 · LEO Pharma is currently exploring temtokibart for inflammation induced anemia. LEO Pharma and argenx, a global immunology company, formed a strategic alliance in 2015 to develop innovative antibody-based solutions for the treatment of chronic inflammation that underlies many skin conditions.
